董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard A. Gonzalez | 男 | Chairman of the Board and Chief Executive Officer | 70 | 2566.20万美元 | 52.33 | 2024-03-18 |
| Melody B. Meyer | 女 | Director | 66 | 37.00万美元 | 1.40 | 2024-03-18 |
| Frederick H. Waddell | 男 | Director | 70 | 37.00万美元 | 2.64 | 2024-03-18 |
| Jennifer Davis | -- | Director | 52 | 4.50万美元 | 未持股 | 2024-03-18 |
| Susan Quaggin | -- | Director | 60 | 2.40万美元 | 未持股 | 2024-03-18 |
| Roxanne S. Austin | 女 | Director | 63 | 38.84万美元 | 3.59 | 2024-03-18 |
| Robert J. Alpern | 男 | Director | 73 | 46.12万美元 | 3.31 | 2024-03-18 |
| Thomas C. Freyman | 男 | Director | 69 | 39.00万美元 | 13.21 | 2024-03-18 |
| Glenn F. Tilton | 男 | Director | 76 | 42.16万美元 | 4.94 | 2024-03-18 |
| Brett J. Hart | 男 | Director | 54 | 38.50万美元 | 1.69 | 2024-03-18 |
| William H.L. Burnside | 男 | Director | 72 | 37.75万美元 | 2.44 | 2024-03-18 |
| Edward J. Rapp | 男 | Director | 66 | 39.50万美元 | 4.04 | 2024-03-18 |
| Rebecca B. Roberts | 女 | Director | 71 | 36.00万美元 | 1.12 | 2024-03-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard A. Gonzalez | 男 | Chairman of the Board and Chief Executive Officer | 70 | 2566.20万美元 | 52.33 | 2024-03-18 |
| Azita Saleki Gerhardt | 女 | Executive Vice President, Chief Operations Officer | 60 | 929.97万美元 | 19.60 | 2024-03-18 |
| Robert A. Michael | 男 | President and Chief Operating Officer | 53 | 1444.13万美元 | 9.86 | 2024-03-18 |
| Nicholas Donoghoe | 男 | Executive Vice President, Chief Business and Strategy Officer | 43 | 未披露 | 未持股 | 2024-03-18 |
| Thomas J. Hudson | 男 | Senior Vice President, Chief Scientific Officer, Global Research | 62 | 未披露 | 未持股 | 2024-03-18 |
| Jeffrey R. Stewart | 男 | Executive Vice President, Chief Commercial Officer | 55 | 1534.96万美元 | 6.23 | 2024-03-18 |
| Perry C. Siatis | 男 | Executive Vice President, General Counsel and Secretary | 49 | 未披露 | 未持股 | 2024-03-18 |
| Scott T. Reents | 男 | Executive Vice President, Chief Financial Officer | 56 | 1018.67万美元 | 0.08 | 2024-03-18 |
| Kevin K. Buckbee | 男 | Senior Vice President, Controller | 58 | 未披露 | 未持股 | 2024-03-18 |
| Roopal Thakkar | 男 | Senior Vice President, Chief Medical Officer, Global Therapeutics | 52 | 未披露 | 未持股 | 2024-03-18 |
| Timothy J. Richmond | 男 | Executive Vice President, Chief Human Resources Officer | 57 | 330.25万美元 | 未持股 | 2024-03-18 |
董事简历
中英对照 | 中文 | 英文- Richard A. Gonzalez
-
Richard A. Gonzalez，2010年至今，担任Pharmaceutical Products Group的执行副总裁；2009年至今，担任Abbott Ventures Inc.的总裁；2007-2009，退休；2006-2007，担任总裁、首席运营官、董事；2002-2006，担任Medical Products Group的总裁、首席运营官、董事；2010年，当选为企业官。
Richard A. Gonzalez,is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013. He served as Abbott's Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott's worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President, Abbott Ventures Inc., Abbott's medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including: Abbott's President and Chief Operating Officer President, Chief Operating Officer of Abbott's Medical Products Group Senior Vice President and President of Abbott's former Hospital Products Division Vice President and President of Abbott's Health Systems Division and Divisional Vice President and General Manager for Abbott's Diagnostics Operations in the United States and Canada. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024. - Richard A. Gonzalez，2010年至今，担任Pharmaceutical Products Group的执行副总裁；2009年至今，担任Abbott Ventures Inc.的总裁；2007-2009，退休；2006-2007，担任总裁、首席运营官、董事；2002-2006，担任Medical Products Group的总裁、首席运营官、董事；2010年，当选为企业官。
- Richard A. Gonzalez,is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013. He served as Abbott's Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott's worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President, Abbott Ventures Inc., Abbott's medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including: Abbott's President and Chief Operating Officer President, Chief Operating Officer of Abbott's Medical Products Group Senior Vice President and President of Abbott's former Hospital Products Division Vice President and President of Abbott's Health Systems Division and Divisional Vice President and General Manager for Abbott's Diagnostics Operations in the United States and Canada. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.
- Melody B. Meyer
-
Melody B. Meyer是一家私人咨询公司Melody Meyer Energy，LLC的总裁，自2016年6月起担任该职位。2011年3月至2016年4月，Meyer女士担任雪佛龙亚太勘探与生产公司总裁。她曾于2008年至2011年担任雪佛龙能源技术公司总裁，并在雪佛龙工作了37年，担任过各种其他职务。Meyer女士还是英国石油公司（BP P.I.C。）和国家油井公司（National Oilwell Varco，Inc.）的董事。
Melody B. Meyer,served as president of Chevron Asia Pacific Exploration and Production Company from March 2011 to April 2016. She previously served as president of Chevron Energy Technology Company from 2008 to 2011. Ms. Meyer held various leadership roles in global and U.S. locations during her thirty-seven year career at Chevron and retired in 2016. Ms. Meyer is president of Melody Meyer Energy, LLC, a private consulting firm, a position she has held since June 2016. Ms. Meyer is also a director at bp p.I.c. and NOV, Inc. - Melody B. Meyer是一家私人咨询公司Melody Meyer Energy，LLC的总裁，自2016年6月起担任该职位。2011年3月至2016年4月，Meyer女士担任雪佛龙亚太勘探与生产公司总裁。她曾于2008年至2011年担任雪佛龙能源技术公司总裁，并在雪佛龙工作了37年，担任过各种其他职务。Meyer女士还是英国石油公司（BP P.I.C。）和国家油井公司（National Oilwell Varco，Inc.）的董事。
- Melody B. Meyer,served as president of Chevron Asia Pacific Exploration and Production Company from March 2011 to April 2016. She previously served as president of Chevron Energy Technology Company from 2008 to 2011. Ms. Meyer held various leadership roles in global and U.S. locations during her thirty-seven year career at Chevron and retired in 2016. Ms. Meyer is president of Melody Meyer Energy, LLC, a private consulting firm, a position she has held since June 2016. Ms. Meyer is also a director at bp p.I.c. and NOV, Inc.
- Frederick H. Waddell
-
Frederick H. Waddell于1975年加入北方信托公司（Northern Trust Corporation），从2009年11月起担任董事会主席，直到2019年1月退休。此前，他曾于2008年至2017年担任首席执行官，2006年至2011年担任总裁，并于10月至2007年再次担任首席执行官。 2006年至2008年到2016年12月担任的首席运营官。此外，Waddell先生还是西北大学董事会成员和AbbVie Inc.董事。
Frederick H. Waddell,joined Northern Trust Corporation in 1975 and served as the chairman of the board from November 2009 until his retirement in January 2019. He previously served as chief executive officer from 2008 through 2017, as president from 2006 through 2011 and again from October to December 2016, and as chief operating officer from 2006 to 2008. Additionally, Mr. Waddell is a member of the Board of Trustees of the Art Institute of Chicago, the Chicago Symphony Orchestra, and Northwestern University, and a director of AbbVie Inc. - Frederick H. Waddell于1975年加入北方信托公司（Northern Trust Corporation），从2009年11月起担任董事会主席，直到2019年1月退休。此前，他曾于2008年至2017年担任首席执行官，2006年至2011年担任总裁，并于10月至2007年再次担任首席执行官。 2006年至2008年到2016年12月担任的首席运营官。此外，Waddell先生还是西北大学董事会成员和AbbVie Inc.董事。
- Frederick H. Waddell,joined Northern Trust Corporation in 1975 and served as the chairman of the board from November 2009 until his retirement in January 2019. He previously served as chief executive officer from 2008 through 2017, as president from 2006 through 2011 and again from October to December 2016, and as chief operating officer from 2006 to 2008. Additionally, Mr. Waddell is a member of the Board of Trustees of the Art Institute of Chicago, the Chicago Symphony Orchestra, and Northwestern University, and a director of AbbVie Inc.
- Jennifer Davis
-
Jennifer Davis，目前担任Procter & Gamble的首席执行官，负责医疗保健。
Jennifer Davis,currently serves as Chief Executive Officer, Health Care at Procter & Gamble. - Jennifer Davis，目前担任Procter & Gamble的首席执行官，负责医疗保健。
- Jennifer Davis,currently serves as Chief Executive Officer, Health Care at Procter & Gamble.
- Susan Quaggin
-
Susan Quaggin,Quaggin博士目前担任Northwestern University Feinberg School of Medicine的Irving S. Cutter教授和医学主席。
Susan Quaggin,Dr. Quaggin currently serves as the Irving S. Cutter Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine. - Susan Quaggin,Quaggin博士目前担任Northwestern University Feinberg School of Medicine的Irving S. Cutter教授和医学主席。
- Susan Quaggin,Dr. Quaggin currently serves as the Irving S. Cutter Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine.
- Roxanne S. Austin
-
Roxanne S. Austin，担任加州私人投资和咨询公司--纽波特海岸奥斯汀投资顾问的总裁。自2004年以来，她担任一家私人投资咨询公司--奥斯汀投资顾问的总裁。从2009年7月至2010年7月，她还担任供应商互联网电视服务--移动网络公司的总裁兼首席执行官。2001年6月至2003年12月，她担任DIRECTV公司的总裁兼首席营运官。她还曾任休斯电子公司的执行副总裁兼首席财务官和德勤会计师事务所的合伙人。她也曾担任AbbVie公司、Target公司、Teledyne公司技术公司和爱立信公司的董事。
Roxanne S. Austin,has served on Crowdstrike Holdings, Inc. board of directors since September 2018.Ms. Austin has served as President of Austin Investment Advisors, a private investment and consulting firm, since January 2004, and has also served as chair of the U.S. Mid-Market Investment Advisory Committee of EQT Partners, a private equity group.Ms. Austin currently serves on the boards of directors of AbbVie Inc., a biopharmaceutical company; Freshworks, Inc., a provider of modern Software-as-a-Service products; and Verizon Communications, a telecommunications company.She previously served on the board of directors of Abbott Laboratories, a provider of pharmaceuticals, medical devices and nutritional products; Teledyne Technologies Incorporated, an industrial conglomerate; LM Ericsson Telephone Company, a networking and telecommunications company; and Target Corporation, a department store retailer.Ms. Austin holds a B.B.A. in Accounting from the University of Texas at San Antonio.Ms. Austin is a member of the California State Society of Certified Public Accountants and the American Institute of Certified Public Accountants. - Roxanne S. Austin，担任加州私人投资和咨询公司--纽波特海岸奥斯汀投资顾问的总裁。自2004年以来，她担任一家私人投资咨询公司--奥斯汀投资顾问的总裁。从2009年7月至2010年7月，她还担任供应商互联网电视服务--移动网络公司的总裁兼首席执行官。2001年6月至2003年12月，她担任DIRECTV公司的总裁兼首席营运官。她还曾任休斯电子公司的执行副总裁兼首席财务官和德勤会计师事务所的合伙人。她也曾担任AbbVie公司、Target公司、Teledyne公司技术公司和爱立信公司的董事。
- Roxanne S. Austin,has served on Crowdstrike Holdings, Inc. board of directors since September 2018.Ms. Austin has served as President of Austin Investment Advisors, a private investment and consulting firm, since January 2004, and has also served as chair of the U.S. Mid-Market Investment Advisory Committee of EQT Partners, a private equity group.Ms. Austin currently serves on the boards of directors of AbbVie Inc., a biopharmaceutical company; Freshworks, Inc., a provider of modern Software-as-a-Service products; and Verizon Communications, a telecommunications company.She previously served on the board of directors of Abbott Laboratories, a provider of pharmaceuticals, medical devices and nutritional products; Teledyne Technologies Incorporated, an industrial conglomerate; LM Ericsson Telephone Company, a networking and telecommunications company; and Target Corporation, a department store retailer.Ms. Austin holds a B.B.A. in Accounting from the University of Texas at San Antonio.Ms. Austin is a member of the California State Society of Certified Public Accountants and the American Institute of Certified Public Accountants.
- Robert J. Alpern
-
Robert J. Alpern，他担任少尉医学教授、内科教授和康涅狄格纽黑文耶鲁医学院院长。自2004年6月，他一直担任少尉医学教授、内科教授以及耶鲁大学医学院院长。从1998年7月至2004年6月，他担任得克萨斯大学西南医学中心的院长。他还担任AbbVie公司的董事，并担任 耶鲁 - 纽黑文医院的董事会董事。
Robert J. Alpern,is Ensign Professor of Medicine and Physiology and Professor of Internal Medicine and Cellular and Molecular Physiology at Yale School of Medicine. Dr. Alpern served as the Dean of Yale School of Medicine and Ensign Professor of Medicine and Professor of Internal Medicine at Yale School of Medicine from June 2004 to January 2020. From July 1998 to May 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical Center. Dr. Alpern served on the board of Yale-New Haven Hospital from October 2005 to January 2020. Dr. Alpern also serves as a director of Abbott Laboratories and Tricida, Inc. - Robert J. Alpern，他担任少尉医学教授、内科教授和康涅狄格纽黑文耶鲁医学院院长。自2004年6月，他一直担任少尉医学教授、内科教授以及耶鲁大学医学院院长。从1998年7月至2004年6月，他担任得克萨斯大学西南医学中心的院长。他还担任AbbVie公司的董事，并担任 耶鲁 - 纽黑文医院的董事会董事。
- Robert J. Alpern,is Ensign Professor of Medicine and Physiology and Professor of Internal Medicine and Cellular and Molecular Physiology at Yale School of Medicine. Dr. Alpern served as the Dean of Yale School of Medicine and Ensign Professor of Medicine and Professor of Internal Medicine at Yale School of Medicine from June 2004 to January 2020. From July 1998 to May 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical Center. Dr. Alpern served on the board of Yale-New Haven Hospital from October 2005 to January 2020. Dr. Alpern also serves as a director of Abbott Laboratories and Tricida, Inc.
- Thomas C. Freyman
-
Thomas C. Freyman，他曾担任Allergan的董事（从2018年到2020年AbbVie收购Allergan plc）。他曾担任Abbott Laboratories的执行副总裁，负责财务和管理（从2015年到2017年退休）。自2004年以来，目前一直担任雅培公司首席财务官、财务执行副总裁。2001年，首次被任命为首席财务官以及财务高级副总裁。1999年至2001年，担任雅培医疗部门的副总裁兼主管。在那之前，他担任了很多财务计划分析职位，包括：雅培国际运作的财务秘书以及公司副总裁兼财务秘书。他获得伊利诺伊大学的本科会计学士学位以及西北大学的工商管理硕士学位。
Thomas C. Freyman,served as a director at Allergan from 2018 to 2020, when AbbVie acquired Allergan plc. Mr. Freyman previously served as executive vice president, finance and administration at Abbott Laboratories from 2015 until his retirement in 2017. He previously served at Abbott as chief financial officer and executive vice president, finance and was first appointed chief financial officer and senior vice president, finance in 2001. Mr. Freyman previously served as a director of Tenneco Inc. from 2013 to 2022 and Hanger, Inc. from 2017 to 2022. - Thomas C. Freyman，他曾担任Allergan的董事（从2018年到2020年AbbVie收购Allergan plc）。他曾担任Abbott Laboratories的执行副总裁，负责财务和管理（从2015年到2017年退休）。自2004年以来，目前一直担任雅培公司首席财务官、财务执行副总裁。2001年，首次被任命为首席财务官以及财务高级副总裁。1999年至2001年，担任雅培医疗部门的副总裁兼主管。在那之前，他担任了很多财务计划分析职位，包括：雅培国际运作的财务秘书以及公司副总裁兼财务秘书。他获得伊利诺伊大学的本科会计学士学位以及西北大学的工商管理硕士学位。
- Thomas C. Freyman,served as a director at Allergan from 2018 to 2020, when AbbVie acquired Allergan plc. Mr. Freyman previously served as executive vice president, finance and administration at Abbott Laboratories from 2015 until his retirement in 2017. He previously served at Abbott as chief financial officer and executive vice president, finance and was first appointed chief financial officer and senior vice president, finance in 2001. Mr. Freyman previously served as a director of Tenneco Inc. from 2013 to 2022 and Hanger, Inc. from 2017 to 2022.
- Glenn F. Tilton
-
Glenn F. Tilton，他是JPMorgan Chase & Co. Chicago公司、Illinois Banking and Financial Services Company的中西部地区主席。他成为摩根大通公司（JPMorgan Chase & Co.）的中西部地区主席，以及其全公司执行委员会成员。从2010年10月到2012年12月，他也曾担任United Continental Holdings公司的董事会非执行董事。从2002年9月到2010年10月，他曾担任UAL Corporation（控股公司）的主席、总裁兼首席执行官，United Air Lines公司（航空运输公司，UAL Corporation的全资子公司）的主席兼首席执行官。他是AbbVie公司和Phillips 66公司的董事。他也曾任职于Lincoln National Corporation（从2002年到2007年）、TXU Corporation（从2005年到2007年）、Corning Incorporated公司（从2010年到2012年）、United Continental Holdings公司（从2001年到2013年）的董事会。
Glenn F. Tilton,service as Chairman and Chief Executive Officer of UAL Corporation, the parent company of United Airlines, as well as Chairman of the Midwest of JPMorgan Chase, has provided him with strong management experience overseeing complex multinational businesses operating in highly regulated industries as well as expertise in financial reporting, risk management, environmental issues, business transformations and capital markets, which assist in his oversight of Phillips 66's management team and financial strategy.He also provides Phillips 66 with extensive experience in the energy industry following a career spanning more than 30 years with Texaco, including serving as Chairman and Chief Executive Officer.He has significant experience with public policy and government affairs through his service on numerous councils and associations including the Chicago Council on Global Affairs, the U.S. Department of Transportation's Future of Aviation Advisory Committee, President Obama's White House Forum on Modernizing Government, and the President's Export Council; he has also served in Chair roles within the Airlines Trade Association and the Star Alliance.He has served as Phillips 66's Lead Independent Director since 2016, where he fulfills an important leadership function in the boardroom and provides an independent voice to the Chief Executive Officer and Executive Chairman in key Board and Company decisions.Mr. Tilton has been a leading participant in conversations with Phillips 66's shareholders in recent years, serving as a critical representative of Phillips 66 shareholders during discussions with the rest of the Board, and in turn representing the perspectives of the full Board in conversations with Phillips 66 shareholders.Mr. Tilton's current and past experiences in significant leadership roles at a variety of public company boards, including Lead Independent Director at AbbVie, Vice Chairman at Chevron, Chairman of United Continental Holdings following the merger between United and Continental Airlines, and a member of the Special Committee at TXU Corporation which negotiated the sale of the company as part of the then-largest leveraged buyout on record, provides him with deep knowledge of corporate governance and board oversight across a range of complex situations. - Glenn F. Tilton，他是JPMorgan Chase & Co. Chicago公司、Illinois Banking and Financial Services Company的中西部地区主席。他成为摩根大通公司（JPMorgan Chase & Co.）的中西部地区主席，以及其全公司执行委员会成员。从2010年10月到2012年12月，他也曾担任United Continental Holdings公司的董事会非执行董事。从2002年9月到2010年10月，他曾担任UAL Corporation（控股公司）的主席、总裁兼首席执行官，United Air Lines公司（航空运输公司，UAL Corporation的全资子公司）的主席兼首席执行官。他是AbbVie公司和Phillips 66公司的董事。他也曾任职于Lincoln National Corporation（从2002年到2007年）、TXU Corporation（从2005年到2007年）、Corning Incorporated公司（从2010年到2012年）、United Continental Holdings公司（从2001年到2013年）的董事会。
- Glenn F. Tilton,service as Chairman and Chief Executive Officer of UAL Corporation, the parent company of United Airlines, as well as Chairman of the Midwest of JPMorgan Chase, has provided him with strong management experience overseeing complex multinational businesses operating in highly regulated industries as well as expertise in financial reporting, risk management, environmental issues, business transformations and capital markets, which assist in his oversight of Phillips 66's management team and financial strategy.He also provides Phillips 66 with extensive experience in the energy industry following a career spanning more than 30 years with Texaco, including serving as Chairman and Chief Executive Officer.He has significant experience with public policy and government affairs through his service on numerous councils and associations including the Chicago Council on Global Affairs, the U.S. Department of Transportation's Future of Aviation Advisory Committee, President Obama's White House Forum on Modernizing Government, and the President's Export Council; he has also served in Chair roles within the Airlines Trade Association and the Star Alliance.He has served as Phillips 66's Lead Independent Director since 2016, where he fulfills an important leadership function in the boardroom and provides an independent voice to the Chief Executive Officer and Executive Chairman in key Board and Company decisions.Mr. Tilton has been a leading participant in conversations with Phillips 66's shareholders in recent years, serving as a critical representative of Phillips 66 shareholders during discussions with the rest of the Board, and in turn representing the perspectives of the full Board in conversations with Phillips 66 shareholders.Mr. Tilton's current and past experiences in significant leadership roles at a variety of public company boards, including Lead Independent Director at AbbVie, Vice Chairman at Chevron, Chairman of United Continental Holdings following the merger between United and Continental Airlines, and a member of the Special Committee at TXU Corporation which negotiated the sale of the company as part of the then-largest leveraged buyout on record, provides him with deep knowledge of corporate governance and board oversight across a range of complex situations.
- Brett J. Hart
-
Brett J. Hart，2012年2月以来，他一直担任执行副总裁、总法律顾问和秘书。从2010年12月到2012年2月，他担任UAL、United和Continental的高级副总裁、总法律顾问和秘书。从2009年6月到2010年12月，他担任Sara Lee Corporation的执行副总裁、总法律顾问和公司秘书。从2005年3月到2009年5月，他担任 Sara Lee Corporatio的副总法律顾问和全球首席合规官。他于2010年加入UAL。
Brett J. Hart,has served as President of UAL and United since May 2020. From March 2019 to May 2020, he served as Executive Vice President and Chief Administrative Officer of UAL and United. From May 2017 to March 2019, he served as Executive Vice President, Chief Administrative Officer and General Counsel of UAL and United. From February 2012 to May 2017, he served as Executive Vice President and General Counsel of UAL and United. Mr. Hart served as acting Chief Executive Officer and principal executive officer of the Company, on an interim basis, from October 2015 to March 2016. From December 2010 to February 2012, he served as Senior Vice President, General Counsel and Secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as Executive Vice President, General Counsel and Corporate Secretary at Sara Lee Corporation, a consumer food and beverage company. From March 2005 to May 2009, Mr. Hart served as Deputy General Counsel and Chief Global Compliance Officer of Sara Lee Corporation. - Brett J. Hart，2012年2月以来，他一直担任执行副总裁、总法律顾问和秘书。从2010年12月到2012年2月，他担任UAL、United和Continental的高级副总裁、总法律顾问和秘书。从2009年6月到2010年12月，他担任Sara Lee Corporation的执行副总裁、总法律顾问和公司秘书。从2005年3月到2009年5月，他担任 Sara Lee Corporatio的副总法律顾问和全球首席合规官。他于2010年加入UAL。
- Brett J. Hart,has served as President of UAL and United since May 2020. From March 2019 to May 2020, he served as Executive Vice President and Chief Administrative Officer of UAL and United. From May 2017 to March 2019, he served as Executive Vice President, Chief Administrative Officer and General Counsel of UAL and United. From February 2012 to May 2017, he served as Executive Vice President and General Counsel of UAL and United. Mr. Hart served as acting Chief Executive Officer and principal executive officer of the Company, on an interim basis, from October 2015 to March 2016. From December 2010 to February 2012, he served as Senior Vice President, General Counsel and Secretary of UAL, United and Continental. From June 2009 to December 2010, Mr. Hart served as Executive Vice President, General Counsel and Corporate Secretary at Sara Lee Corporation, a consumer food and beverage company. From March 2005 to May 2009, Mr. Hart served as Deputy General Counsel and Chief Global Compliance Officer of Sara Lee Corporation.
- William H.L. Burnside
-
William H.L. Burnside，Burnside先生是The Boston Consulting Group BCG的一位退休高级副总裁兼董事，目前担任顾问。在1987年成为BCG洛杉矶办事处的管理合伙人之前，他曾在BCG的伦敦和芝加哥办事处任职，为电信，媒体，国防，金融服务和制造业的客户提供服务。Burnside先生是南加州和奥杜邦加利福尼亚州执行服务部门的董事。
William H.L. Burnside,is a retired senior vice president and director at The Boston Consulting Group (BCG), where he currently serves as an advisor. Prior to becoming managing partner of BCG's Los Angeles office in 1987, he worked in BCG's London and Chicago offices, servicing clients in telecommunications, media, defense, financial services, and manufacturing. - William H.L. Burnside，Burnside先生是The Boston Consulting Group BCG的一位退休高级副总裁兼董事，目前担任顾问。在1987年成为BCG洛杉矶办事处的管理合伙人之前，他曾在BCG的伦敦和芝加哥办事处任职，为电信，媒体，国防，金融服务和制造业的客户提供服务。Burnside先生是南加州和奥杜邦加利福尼亚州执行服务部门的董事。
- William H.L. Burnside,is a retired senior vice president and director at The Boston Consulting Group (BCG), where he currently serves as an advisor. Prior to becoming managing partner of BCG's Los Angeles office in 1987, he worked in BCG's London and Chicago offices, servicing clients in telecommunications, media, defense, financial services, and manufacturing.
- Edward J. Rapp
-
Edward J. Rapp于2014年担任卡特彼勒公司（Caterpillar Inc.）集团资源行业总裁，2016年年中退休。他曾于2013年和2014年在卡特彼勒担任集团总裁，并于2010年至2013年担任首席财务官，2007年被任命为集团总裁。Rapp先生目前是FM Global的董事会成员。他目前是密苏里大学商业战略发展委员会的成员。
Edward J. Rapp,served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid-2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. He also serves as a director of Xos, Inc. He is currently a member of the University of Missouri College of Business Advisory Board. Mr. Rapp previously served as a director of FM Global. - Edward J. Rapp于2014年担任卡特彼勒公司（Caterpillar Inc.）集团资源行业总裁，2016年年中退休。他曾于2013年和2014年在卡特彼勒担任集团总裁，并于2010年至2013年担任首席财务官，2007年被任命为集团总裁。Rapp先生目前是FM Global的董事会成员。他目前是密苏里大学商业战略发展委员会的成员。
- Edward J. Rapp,served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid-2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007. He also serves as a director of Xos, Inc. He is currently a member of the University of Missouri College of Business Advisory Board. Mr. Rapp previously served as a director of FM Global.
- Rebecca B. Roberts
-
Rebecca B. Roberts 从 2006 年到 2011 年退休，Roberts 女士担任Chevron Pipe Line Company 的总裁，Chevron Pipe Line Company 是一家在美国境内运输原油、精炼石油产品、液化石油气、天然气和化学品的管道公司。 从 2003 年到 2006 年，她担任Chevron Global Power Generation 总裁。 从 2015 年到 2018 年，她还曾在 Enbridge, Inc. 董事会任职。Roberts 女士是 Abbvie, Inc. 和 MSA Safety, Inc. 的董事会成员，并担任薪酬委员会主席 委员会。
Rebecca B. Roberts,served as president of Chevron Pipe Line Company from 2006 until her retirement in 2011. She previously served as the president of Chevron Global Power Generation from 2003 to 2006, in addition to various technical and management positions during her thirty-six year career with Chevron. Ms. Roberts began her career as a chemist and research scientist. Ms. Roberts currently serves on the board of directors at Black Hills Corporation and MSA Safety Incorporated. Ms. Roberts served as a director of Enbridge, Inc. from 2015 to 2018. - Rebecca B. Roberts 从 2006 年到 2011 年退休，Roberts 女士担任Chevron Pipe Line Company 的总裁，Chevron Pipe Line Company 是一家在美国境内运输原油、精炼石油产品、液化石油气、天然气和化学品的管道公司。 从 2003 年到 2006 年，她担任Chevron Global Power Generation 总裁。 从 2015 年到 2018 年，她还曾在 Enbridge, Inc. 董事会任职。Roberts 女士是 Abbvie, Inc. 和 MSA Safety, Inc. 的董事会成员，并担任薪酬委员会主席 委员会。
- Rebecca B. Roberts,served as president of Chevron Pipe Line Company from 2006 until her retirement in 2011. She previously served as the president of Chevron Global Power Generation from 2003 to 2006, in addition to various technical and management positions during her thirty-six year career with Chevron. Ms. Roberts began her career as a chemist and research scientist. Ms. Roberts currently serves on the board of directors at Black Hills Corporation and MSA Safety Incorporated. Ms. Roberts served as a director of Enbridge, Inc. from 2015 to 2018.
高管简历
中英对照 | 中文 | 英文- Richard A. Gonzalez
Richard A. Gonzalez，2010年至今，担任Pharmaceutical Products Group的执行副总裁；2009年至今，担任Abbott Ventures Inc.的总裁；2007-2009，退休；2006-2007，担任总裁、首席运营官、董事；2002-2006，担任Medical Products Group的总裁、首席运营官、董事；2010年，当选为企业官。
Richard A. Gonzalez,is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013. He served as Abbott's Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott's worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President, Abbott Ventures Inc., Abbott's medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including: Abbott's President and Chief Operating Officer President, Chief Operating Officer of Abbott's Medical Products Group Senior Vice President and President of Abbott's former Hospital Products Division Vice President and President of Abbott's Health Systems Division and Divisional Vice President and General Manager for Abbott's Diagnostics Operations in the United States and Canada. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.- Richard A. Gonzalez，2010年至今，担任Pharmaceutical Products Group的执行副总裁；2009年至今，担任Abbott Ventures Inc.的总裁；2007-2009，退休；2006-2007，担任总裁、首席运营官、董事；2002-2006，担任Medical Products Group的总裁、首席运营官、董事；2010年，当选为企业官。
- Richard A. Gonzalez,is the Chairman and Chief Executive Officer of AbbVie, a position he has held since 2013. He served as Abbott's Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott's worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing. He also served as President, Abbott Ventures Inc., Abbott's medical technology investment arm, from 2009 to 2011. Mr. Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including: Abbott's President and Chief Operating Officer President, Chief Operating Officer of Abbott's Medical Products Group Senior Vice President and President of Abbott's former Hospital Products Division Vice President and President of Abbott's Health Systems Division and Divisional Vice President and General Manager for Abbott's Diagnostics Operations in the United States and Canada. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024.
- Azita Saleki Gerhardt
Azita Saleki Gerhardt博士，她目前担任AbbVie Inc.的执行副总裁，负责运营，这是一家全球研究驱动的生物制药公司，致力于为一些世界上最复杂和关键的条件开发创新的先进疗法，此前曾担任运营高级副总裁（从2013年到2018年）。艾伯维（AbbVie）成立于2013年，是雅培（Abbott Laboratories）的子公司。她在Abbott Laboratories工作了20多年，担任各种高级管理职位，专注于运营、制造和质量。
Azita Saleki Gerhardt,is AbbVie's Executive Vice President, Chief Operations Officer. She served as Executive Vice President, Operations from 2018 to July 2023, and as Senior Vice President, Operations from 2013 to 2018. Dr. Saleki-Gerhardt served as Abbott's Vice President, Pharmaceuticals Manufacturing and Supply from 2011 to 2012, and as Divisional Vice President, Quality Assurance, Global Pharmaceutical Operations from 2008 to 2011. Dr. Saleki-Gerhardt joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in December 2012. She serves on the board of Entegris Inc.- Azita Saleki Gerhardt博士，她目前担任AbbVie Inc.的执行副总裁，负责运营，这是一家全球研究驱动的生物制药公司，致力于为一些世界上最复杂和关键的条件开发创新的先进疗法，此前曾担任运营高级副总裁（从2013年到2018年）。艾伯维（AbbVie）成立于2013年，是雅培（Abbott Laboratories）的子公司。她在Abbott Laboratories工作了20多年，担任各种高级管理职位，专注于运营、制造和质量。
- Azita Saleki Gerhardt,is AbbVie's Executive Vice President, Chief Operations Officer. She served as Executive Vice President, Operations from 2018 to July 2023, and as Senior Vice President, Operations from 2013 to 2018. Dr. Saleki-Gerhardt served as Abbott's Vice President, Pharmaceuticals Manufacturing and Supply from 2011 to 2012, and as Divisional Vice President, Quality Assurance, Global Pharmaceutical Operations from 2008 to 2011. Dr. Saleki-Gerhardt joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in December 2012. She serves on the board of Entegris Inc.
- Robert A. Michael
Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管，并于2015年至2016年担任Abbvie副总裁、财务主管，2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培，Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。
Robert A. Michael,is AbbVie's President and Chief Operating Officer. Mr. Michael previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024. The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.- Robert A. Michael自2017年3月1日起担任副总裁、总监。他于2015年成为Abbvie高管，并于2015年至2016年担任Abbvie副总裁、财务主管，2013年至2015年担任商业运营副总裁、财务规划和分析副总裁。在雅培，Michael先生从2010年到2012年担任营养供应链部门总监。Michael先生于1993年加入雅培。
- Robert A. Michael,is AbbVie's President and Chief Operating Officer. Mr. Michael previously served as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018. He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013. At Abbott, Mr. Michael served as Division Controller, Nutrition Supply Chain from 2010 to 2012. Mr. Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017. On February 14, 2024, the Board of Directors of AbbVie unanimously selected Mr. Michael to succeed Mr. Gonzalez as the Company's Chief Executive Officer. Mr. Gonzalez will retire from the role of Chief Executive Officer and become Executive Chairman of the Board of Directors, effective July 1, 2024. The Board also appointed Mr. Michael as a member of the Board of Directors as a Class II director, effective July 1, 2024.
- Nicholas Donoghoe
Nicholas Donoghoe是AbbVie企业创新高级副总裁。 他之前曾在麦肯锡公司（McKinsey＆Company）担任合伙人，领导该公司的西海岸制药和生物技术业务。 Donoghoe博士于2007年加入公司，并支持在肿瘤学，免疫学和基层医疗等治疗领域的多次成功推出。 他于2019年加入AbbVie。
Nicholas Donoghoe,is AbbVie's Executive Vice President, Chief Business and Strategy Officer. He has previously served as AbbVie's Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020. Prior to joining AbbVie in 2019, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.- Nicholas Donoghoe是AbbVie企业创新高级副总裁。 他之前曾在麦肯锡公司（McKinsey＆Company）担任合伙人，领导该公司的西海岸制药和生物技术业务。 Donoghoe博士于2007年加入公司，并支持在肿瘤学，免疫学和基层医疗等治疗领域的多次成功推出。 他于2019年加入AbbVie。
- Nicholas Donoghoe,is AbbVie's Executive Vice President, Chief Business and Strategy Officer. He has previously served as AbbVie's Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020. Prior to joining AbbVie in 2019, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.
- Thomas J. Hudson
Thomas J. Hudson是AbbVie研究与开发高级副总裁兼首席科学官。 他曾于2016年至2019年担任副总裁，肿瘤发现与早期开发负责人。在加入AbbVie之前，Hudson博士曾在安大略省癌症研究所担任总裁兼科学总监。 他还曾担任麦吉尔大学和魁北克基因组创新中心的创始人和主任，以及怀特海德/麻省理工学院基因组研究中心的助理主任。
Thomas J. Hudson,is AbbVie's Senior Vice President, Chief Scientific Officer, Global Research. He previously served as Senior Vice President, Research & Development and Chief Scientific Officer from 2019 to 2023, and as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019. Prior to joining AbbVie, Dr. Hudson served at the Ontario Institute for Cancer Research as President and Scientific Director. He also previously served as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson was first appointed as an AbbVie corporate officer in July 2019.- Thomas J. Hudson是AbbVie研究与开发高级副总裁兼首席科学官。 他曾于2016年至2019年担任副总裁，肿瘤发现与早期开发负责人。在加入AbbVie之前，Hudson博士曾在安大略省癌症研究所担任总裁兼科学总监。 他还曾担任麦吉尔大学和魁北克基因组创新中心的创始人和主任，以及怀特海德/麻省理工学院基因组研究中心的助理主任。
- Thomas J. Hudson,is AbbVie's Senior Vice President, Chief Scientific Officer, Global Research. He previously served as Senior Vice President, Research & Development and Chief Scientific Officer from 2019 to 2023, and as Vice President, Head of Oncology Discovery and Early Development from 2016 to 2019. Prior to joining AbbVie, Dr. Hudson served at the Ontario Institute for Cancer Research as President and Scientific Director. He also previously served as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson was first appointed as an AbbVie corporate officer in July 2019.
- Jeffrey R. Stewart
Jeffrey R. Stewart是艾伯维（AbbVie）美国商业运营高级副总裁。 斯图尔特先生曾于2013年至2018年担任AbbVie商业运营总裁。在AbbVie从雅培离职之前，他曾担任美国雅培专有制药部门副总裁。 斯图尔特先生于1992年加入雅培。
Jeffrey R. Stewart,is AbbVie's Executive Vice President, Chief Commercial Officer. He previously served as Senior Vice President, U.S. Commercial Operations from 2018 to 2020 and as AbbVie's President, Commercial Operations from 2013 to 2018. Prior to AbbVie's separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.- Jeffrey R. Stewart是艾伯维（AbbVie）美国商业运营高级副总裁。 斯图尔特先生曾于2013年至2018年担任AbbVie商业运营总裁。在AbbVie从雅培离职之前，他曾担任美国雅培专有制药部门副总裁。 斯图尔特先生于1992年加入雅培。
- Jeffrey R. Stewart,is AbbVie's Executive Vice President, Chief Commercial Officer. He previously served as Senior Vice President, U.S. Commercial Operations from 2018 to 2020 and as AbbVie's President, Commercial Operations from 2013 to 2018. Prior to AbbVie's separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States. Mr. Stewart joined Abbott in 1992 and was first appointed as an AbbVie corporate officer in December 2018.
- Perry C. Siatis
Perry C. Siatis是AbbVie的执行副总裁、总法律顾问和秘书。Siatis先生曾于2021年9月至2022年10月担任高级副总裁兼副总法律顾问。2013年至2021年，Siatis先生还担任过各种职务，包括高级副总裁、法律和首席道德与合规官；法律交易和研发/联盟管理高级副总裁兼首席道德与合规官；生物战略发展和法律监管副总裁。Siatis先生于2005年加入Abbott，并于2022年10月首次被任命为AbbVie公司高管。
Perry C. Siatis,is AbbVie's Executive Vice President, General Counsel and Secretary. Mr. Siatis previously served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022. From 2013 until 2021, Mr. Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer and Vice President, Biologic Strategic Development and Legal Regulatory. Mr. Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.- Perry C. Siatis是AbbVie的执行副总裁、总法律顾问和秘书。Siatis先生曾于2021年9月至2022年10月担任高级副总裁兼副总法律顾问。2013年至2021年，Siatis先生还担任过各种职务，包括高级副总裁、法律和首席道德与合规官；法律交易和研发/联盟管理高级副总裁兼首席道德与合规官；生物战略发展和法律监管副总裁。Siatis先生于2005年加入Abbott，并于2022年10月首次被任命为AbbVie公司高管。
- Perry C. Siatis,is AbbVie's Executive Vice President, General Counsel and Secretary. Mr. Siatis previously served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022. From 2013 until 2021, Mr. Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer and Vice President, Biologic Strategic Development and Legal Regulatory. Mr. Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.
- Scott T. Reents
Scott T. Reents是AbbVie的执行副总裁兼首席财务官。他曾于2022年6月至2022年11月担任高级副总裁兼首席财务官，2019年至2022年6月份担任税务和财政部副总裁，2013年至2019年担任税务部副总裁。Reents先生于2008年加入Abbott，并于2022年6月首次被任命为AbbVie公司高管。
Scott T. Reents,is AbbVie's Executive Vice President, Chief Financial Officer. He previously served as Senior Vice President, Chief Financial Officer from June 2022 to November 2022, as Vice President, Tax and Treasury from 2019 to June 2022, and as Vice President, Tax from 2013 to 2019. Mr. Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.- Scott T. Reents是AbbVie的执行副总裁兼首席财务官。他曾于2022年6月至2022年11月担任高级副总裁兼首席财务官，2019年至2022年6月份担任税务和财政部副总裁，2013年至2019年担任税务部副总裁。Reents先生于2008年加入Abbott，并于2022年6月首次被任命为AbbVie公司高管。
- Scott T. Reents,is AbbVie's Executive Vice President, Chief Financial Officer. He previously served as Senior Vice President, Chief Financial Officer from June 2022 to November 2022, as Vice President, Tax and Treasury from 2019 to June 2022, and as Vice President, Tax from 2013 to 2019. Mr. Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.
- Kevin K. Buckbee
Kevin K. Buckbee，是艾伯维高级副总裁、财务总监。Buckbee先生此前曾在2016年1月至2023年3月期间担任艾伯维全球商业运营副总裁兼财务总监，并在2013年艾伯维从雅培分离至2015年12月期间担任美国商业运营副总裁兼财务总监。Buckbee先生于1991年加入雅培，曾在这家金融机构担任多个职位。
Kevin K. Buckbee,is AbbVie's Senior Vice President, Controller. Mr. Buckbee previously served as AbbVie's Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, US Commercial Operations from AbbVie's separation from Abbott in 2013 until December 2015. Mr. Buckbee joined Abbott in 1991 and held several positions in the finance organization.- Kevin K. Buckbee，是艾伯维高级副总裁、财务总监。Buckbee先生此前曾在2016年1月至2023年3月期间担任艾伯维全球商业运营副总裁兼财务总监，并在2013年艾伯维从雅培分离至2015年12月期间担任美国商业运营副总裁兼财务总监。Buckbee先生于1991年加入雅培，曾在这家金融机构担任多个职位。
- Kevin K. Buckbee,is AbbVie's Senior Vice President, Controller. Mr. Buckbee previously served as AbbVie's Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, US Commercial Operations from AbbVie's separation from Abbott in 2013 until December 2015. Mr. Buckbee joined Abbott in 1991 and held several positions in the finance organization.
- Roopal Thakkar
Roopal Thakkar，担任艾伯维全球治疗高级副总裁、首席医疗官。此前，他曾于2022年底至2023年12月初担任艾伯维发展和监管事务高级副总裁兼首席医疗官，并于2019年至2022年担任全球监管事务和研发质量保证副总裁，并于2015年至2019年担任全球监管事务副总裁。Thakkar博士于2003年加入雅培，并于2023年12月首次被任命为公司高管。
Roopal Thakkar,serves as AbbVie's Senior Vice President, Chief Medical Officer, Global Therapeutics. He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from late 2022 until early December 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019. Dr. Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.- Roopal Thakkar，担任艾伯维全球治疗高级副总裁、首席医疗官。此前，他曾于2022年底至2023年12月初担任艾伯维发展和监管事务高级副总裁兼首席医疗官，并于2019年至2022年担任全球监管事务和研发质量保证副总裁，并于2015年至2019年担任全球监管事务副总裁。Thakkar博士于2003年加入雅培，并于2023年12月首次被任命为公司高管。
- Roopal Thakkar,serves as AbbVie's Senior Vice President, Chief Medical Officer, Global Therapeutics. He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from late 2022 until early December 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019. Dr. Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.
- Timothy J. Richmond
Timothy J. Richmond是Abbvie的高级人力资源副总裁。2008年至2012年，他担任雅培的薪酬与福利部门副总裁，2007年至2008年，他担任集团人才与奖励部门副总裁，2006年至2007年，他担任人才收购部门副总裁。里士满于2006年加入雅培。
Timothy J. Richmond,is AbbVie's Executive Vice President, Chief Human Resources Officer. He served as Senior Vice President, Human Resources from 2013 to 2018. Mr. Richmond served as Abbott's Divisional Vice President of Compensation & Benefits from 2008 to 2012, as Group Vice President of Talent and Rewards from 2007 to 2008 and as Divisional Vice President of Talent Acquisition from 2006 to 2007. Mr. Richmond joined Abbott in 2006 and was first appointed as an AbbVie corporate officer in December 2012.- Timothy J. Richmond是Abbvie的高级人力资源副总裁。2008年至2012年，他担任雅培的薪酬与福利部门副总裁，2007年至2008年，他担任集团人才与奖励部门副总裁，2006年至2007年，他担任人才收购部门副总裁。里士满于2006年加入雅培。
- Timothy J. Richmond,is AbbVie's Executive Vice President, Chief Human Resources Officer. He served as Senior Vice President, Human Resources from 2013 to 2018. Mr. Richmond served as Abbott's Divisional Vice President of Compensation & Benefits from 2008 to 2012, as Group Vice President of Talent and Rewards from 2007 to 2008 and as Divisional Vice President of Talent Acquisition from 2006 to 2007. Mr. Richmond joined Abbott in 2006 and was first appointed as an AbbVie corporate officer in December 2012.